Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

AIDS

Volumn 22, Issue 14, 2008, Pages 1779-1787

  Pessôa, Mário Guimarães ^a   Gazzard, Brian ^b   Huang, Anna K ^c   Brandão Mello, Carlos E ^d   Cassetti, Isabel ^e   Mendes Corrěa, Maria Cassia ^f   Soriano, Vicente ^g   Phiri, Phillip ^h   Hall, Andrea ^h   Brett Smith, Helena ^h  

^a INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d HOSPITAL UNIVERSITÁRIO GAFFRÉE E GUINLE   (Brazil)

^e Fundacion Centro de Estudios Infectologicos   (Argentina)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

Entecavir; HAART; HBV; Hepatitis B; HIV; Lamivudine; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PLACEBO; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TESTIS TUMOR; VIREMIA; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; LINEAR MODELS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VIRUS REPLICATION;

EID: 63849149651     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830b3ab5     Document Type: Article

References (30)

1. Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001; 32:1487-1493.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
3. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
4. Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805.
5. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163:1138-1140.
6. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
7. Alberti A, ClumeckN, Collins S, Gerlich W, LundgrenJ, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
8. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al., BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 (Suppl 1): 1-41.
9. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
10. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221-240.
11. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-inter-feron therapy? A statistical analysis of predictive factors. Hepatology 1989; 10:761-763.
12. Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999; 37:3013-3016.
13. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306.
14. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
15. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9:257-262.
16. Benhamou Y, Bochet M, Thibault V, CalvezV, FievetMH, VigP, et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label pilot study. Lancet 2001; 358:718-723.
17. Benhamou Y, Thibault V, VigP, CalvezV, Marcelin AG, Fievet MH, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44:62-67.
18. Sherman M, Yurdaydin C, SollanoJ, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049.
19. Bristol-Myers Squibb Company. BaracludeTM (entecavir): prescribing information. 2007.
20. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
21. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
22. Lai CL, DienstagJ, Schiff E, Leung NW, AtkinsM, HuntC, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696.
23. Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Eggers B, Xu D, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients [abstract 781]. J Hepatol 2007; 46 (Suppl 1):S294.
24. Nelson M, Portsmouth S, StebbingJ, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003; 17:F7-F10.
25. Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Antihepatitis B virus efficacy of tenofovir disoproxil in HIV-infected patients. Hepatology 2006; 43:548-555.
26. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N EnglJ Med 2004; 351:1521-1531.
27. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001 -1010.
28. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N EnglJ Med 2006; 354:1011-1020.
29. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, et al. Prevalence and characterization of lamivudine-resis-tant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17:1 649-1 657.
30. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at http://www.aid sinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 27, 2008.